Pharmaceuticals News and Research

RSS

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that the launch of Soliris (eculizumab) as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than previously expected.

2 Jun 2010

LAB Research's Canadian laboratory receives OECD-GLP compliance status

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that its Canadian laboratory has received a Good Laboratory Practices recognition from the Standards Council of Canada.

2 Jun 2010

LEO Pharma to find alternative solution to withdraw pharmaceutical products from Greek market

LEO Pharma is in dialogue with the Greek authorities to find an alternative solution to withdrawing the company's pharmaceutical products from the Greek market.

2 Jun 2010

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Santarus, Inc., a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX® for the treatment of patients with travelers' diarrhea.

2 Jun 2010

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Proceedings of the National Academy of Sciences (PNAS) by Alnylam scientists and collaborators from Mount Sinai School of Medicine. In the new study, Alnylam and Mount Sinai scientists discovered a novel class of virus-produced small non-coding RNAs, called small viral RNAs (svRNAs), which play a critical role in the replication of influenza A virus.

2 Jun 2010

TU Delft, MI Labs combine microPET and microSPECT into Versatile Emission Computed Tomography device

TU Delft and Molecular Imaging Labs (MI Labs) have succeeded in combining two forms of medical imaging techniques into one piece of equipment. These techniques are particularly useful for cancer research.

2 Jun 2010

Generex awarded new patents in Japan and Ukraine for buccal drug delivery platform technologies

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded two new patents in Japan and Ukraine.

2 Jun 2010

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.

2 Jun 2010

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals, Inc. today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.

2 Jun 2010

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

2 Jun 2010

Teva Pharmaceutical launches Gianvi Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commercially launched Gianvi (Drospirenone and Ethinyl Estradiol) Tablets, the Company's generic version of Bayer's Yaz® Tablets.

2 Jun 2010

Tetraphase Pharmaceuticals raises $45M in Series C financing

Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing.

2 Jun 2010

Businesses fret penalties, seek opportunities in health overhaul

Some small businesses may get financial help as part of the health overhaul that could cover up to 35 percent of business's premium costs for insuring employees in the form of new tax credits, Kaiser Health News explains in a consumer column.

2 Jun 2010

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

1 Jun 2010

PAREXEL International establishes new brand identity "Right Where You Need Us"

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has established the new brand identity "Right Where You Need Us," which reflects various transformation initiatives focused on meeting the diverse requirements of the Company's clients.

From Parexel 1 Jun 2010

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.

1 Jun 2010

MediSapiens completes $1M seed round investment for personalized cancer medicine software

MediSapiens, world's first software company for personalized cancer medicine in oncology clinics and drug development, completed $ 1 million (EUR 0.8 million) seed round investment from Veraventure, ETFIII advised by Eqvitec Partners, VTT Ventures and Lifeline Ventures.

1 Jun 2010

Akela Pharma fourth-quarter consolidated net loss increases to $14.1M

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months and year ended December 31, 2009.

1 Jun 2010

Free online seminars on Reaction Progress Kinetic Analysis

Reaction Progress Kinetic Analysis (RPKA) streamlines kinetic studies by exploiting extensive data available from accurate in situ monitoring of global reaction progress under synthetically relevant conditions, where the concentrations of two or more reactants are changing simultaneously – in fact, in the same manner that they are expected to change during practical synthesis.

31 May 2010

Pharmaceuticals News and Research

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

LAB Research's Canadian laboratory receives OECD-GLP compliance status

LEO Pharma to find alternative solution to withdraw pharmaceutical products from Greek market

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

TU Delft, MI Labs combine microPET and microSPECT into Versatile Emission Computed Tomography device

Generex awarded new patents in Japan and Ukraine for buccal drug delivery platform technologies

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Teva Pharmaceutical launches Gianvi Tablets

Tetraphase Pharmaceuticals raises $45M in Series C financing

Businesses fret penalties, seek opportunities in health overhaul

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

PAREXEL International establishes new brand identity "Right Where You Need Us"

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

MediSapiens completes $1M seed round investment for personalized cancer medicine software

Akela Pharma fourth-quarter consolidated net loss increases to $14.1M

Free online seminars on Reaction Progress Kinetic Analysis

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News